CMPX — Compass Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1738021 ·
Last close
$2.20
Market Cap
$396.19M
52W High
$6.84
52W Low
$1.61
ADV30
12,663,445
Next earnings
2026-05-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -20,299,000 | -18,317,000 | 205,170,000 | 55,168,000 | 18,697,000 |
| Dec 2025 | 0 | — | -17,990,000 | -15,716,000 | 219,588,000 | 30,643,000 | 22,797,000 |
| Sep 2025 | 0 | — | -15,817,000 | -14,259,000 | 231,259,000 | 46,212,000 | 21,646,000 |
| Jun 2025 | 0 | — | -21,066,000 | -19,881,000 | 116,698,000 | 22,856,000 | 23,491,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-49,143,000
Investing CF
$-93,306,000
Financing CF
$129,609,000
CapEx
$-25,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-431,172,000
Inventory
—
Receivables
—
ST Investments
$178,263,000
EBIT TTM
$-72,839,000
Pretax Income TTM
$-66,489,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -72,839,000 | -66,489,000 | 219,588,000 | 22,797,000 | — | -49,143,000 |
| Dec 2024 | 850,000 | -56,625,000 | -49,375,000 | 140,403,000 | 15,170,000 | — | -44,855,000 |
| Dec 2023 | 0 | -50,363,000 | -42,494,000 | 156,875,000 | 8,337,000 | — | -40,618,000 |
| Dec 2022 | 0 | -41,655,000 | -39,225,000 | 199,645,000 | 18,007,000 | — | -34,125,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.46
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZURA | Zura Bio Ltd | $399.45M | $4.21 | — |
| IPSC | Century Therapeutics, Inc. | $391.37M | $2.17 | — |
| LXEO | Lexeo Therapeutics, Inc. | $403.60M | $5.14 | — |
| CCCC | C4 Therapeutics, Inc. | $385.88M | $3.49 | — |
| REPL | Replimune Group, Inc. | $379.83M | $4.60 | — |
News headlines (Yahoo Finance, 1h cache)
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
2026-05-21 21:00 · Yahoo
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M
2026-05-18 04:50 · Yahoo
Compass Therapeutics to Participate in Upcoming May Investor Events
2026-05-12 11:30 · Yahoo
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)
2026-05-05 12:16 · Yahoo
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
2026-05-05 11:30 · Yahoo
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity?
2026-04-29 11:04 · Yahoo
Micron initiated, Rambus downgraded: Wall Street's top analyst calls
2026-04-28 14:19 · Yahoo
Compass Therapeutics’s stock crashes after OS miss in BTC trial
2026-04-28 11:21 · Yahoo
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
2026-04-28 00:01 · Yahoo
Compass Therapeutics Touts “Stunning” PFS Win in COMPANION-002 as Crossover Muddy OS Data
2026-04-27 20:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.